Sprint Bioscience AB Cash Flow Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2016
Net Income	91.74	-18.28	-0.44	-60.17	-25.08	Upgrade
Depreciation & Amortization	1.07	0.96	0.45	0.62	0.59	Upgrade
Other Operating Activities	-	-	-	-	-0.06	Upgrade
Change in Accounts Receivable	6.02	-4.25	-2.55	-0.09	-0.1	Upgrade
Change in Accounts Payable	-1.04	-0.23	2.02	0.84	-0.43	Upgrade
Change in Other Net Operating Assets	-14.26	-1.56	23.39	-0.25	-15.04	Upgrade
Operating Cash Flow	83.53	-23.36	22.87	-59.05	-40.12	Upgrade
Capital Expenditures	-0.09	-1.3	-2.45	-	-2.71	Upgrade
Investment in Securities	0.04	-	-	-	-	Upgrade
Investing Cash Flow	-0.05	-1.3	-2.45	-	-2.71	Upgrade
Short-Term Debt Issued	-	-	-	-	10	Upgrade
Total Debt Issued	-	-	-	-	10	Upgrade
Net Debt Issued (Repaid)	-	-	-	-	10	Upgrade
Issuance of Common Stock	23.45	-	0.02	22.41	88.8	Upgrade
Other Financing Activities	-5.28	-0.23	-	-4.51	-12.41	Upgrade
Financing Cash Flow	18.17	-0.23	0.02	17.9	86.39	Upgrade
Net Cash Flow	101.65	-24.88	20.44	-41.15	43.57	Upgrade
Free Cash Flow	83.44	-24.65	20.42	-59.05	-42.82	Upgrade
Free Cash Flow Margin	49.85%	-37.27%	39.50%	-71149.40%	-122.26%	Upgrade
Free Cash Flow Per Share	0.90	-0.35	0.29	-1.40	-1.49	Upgrade
Cash Interest Paid	6.21	0.04	0.39	0.11	0.37	Upgrade
Levered Free Cash Flow	52.4	-18.16	19.99	-36.81	-23.87	Upgrade
Unlevered Free Cash Flow	52.67	-18.14	19.99	-36.81	-23.7	Upgrade
Change in Working Capital	-9.28	-6.04	22.86	0.5	-15.57	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.